Natera experienced a notable pullback driven largely by broad profit-taking following an extended rally that recently pushed shares to fresh peak levels. After a momentum-driven run supported by key clinical and regulatory wins, including international approval for its Signatera minimal residual disease test as well as encouraging data presentations at oncology conferences, market participants opted to lock in substantial recent gains. This rapid intraday reversal highlights heightened short-term volatility as the stock encountered stiff technical resistance at extended high valuations.

Underlying the selling pressure is growing market scrutiny regarding the company’s valuation. Following an exceptional year-to-date gain, Natera’s…